{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:39:38Z","timestamp":1791315578486,"version":"4.3.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01765","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T07:39:58Z","timestamp":1597131598000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":49,"title":["Eosinophilia Associated With CD3\u2212CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients"],"prefix":"10.3389","volume":"11","author":[{"given":"Caroline","family":"Carpentier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Verbanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Schanden\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Heimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Tr\u00e9pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Cogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.7326\/0003-4819-68-6-1220","article-title":"The hypereosinophilic syndromes","volume":"68","author":"Hardy","year":"1968","journal-title":"Ann Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine."},{"key":"B3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJM199402243300804","article-title":"Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome","volume":"330","author":"Cogan","year":"1994","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype","volume":"93","author":"Lefevre","year":"2014","journal-title":"Medicine."},{"key":"B6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am."},{"key":"B7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1046\/j.1365-2141.2000.02097.x","article-title":"Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome","volume":"109","author":"Roufosse","year":"2000","journal-title":"Br J Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3324\/haematol.2014.118042","article-title":"CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder","volume":"100","author":"Lefevre","year":"2015","journal-title":"Haematologica."},{"key":"B10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev.med.54.101601.152431","article-title":"The hypereosinophilic syndrome revisited","volume":"54","author":"Roufosse","year":"2003","journal-title":"Annu Rev Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1067\/mai.2002.127003","article-title":"High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome","volume":"110","author":"de Lavareille","year":"2002","journal-title":"J Allergy Clin Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3109\/10428194.2014.976823","article-title":"Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma","volume":"56","author":"Roufosse","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jaci.2013.06.037","article-title":"Marked and persistent eosinophilia in the absence of clinical manifestations","volume":"133","author":"Chen","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3324\/haematol.2013.091264","article-title":"Episodic angioedema with eosinophilia (gleich syndrome) is a multilineage cell cycling disorder","volume":"100","author":"Khoury","year":"2015","journal-title":"Haematologica."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.001","article-title":"Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (gleich's syndrome): frequency, clinical implication and prognosis","author":"Abisror","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJM198406213102501","article-title":"Episodic angioedema associated with eosinophilia","volume":"310","author":"Gleich","year":"1984","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3109\/10428199309067941","article-title":"Lymphomatous polyarthritis in patients with peripheral T-cell lymphoma","volume":"11","author":"Tachibana","year":"1993","journal-title":"Leuk Lymphoma."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1161\/CIRCULATIONAHA.118.036124","article-title":"Coronary arteries and the cell count","volume":"139","author":"Divanji","year":"2019","journal-title":"Circulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00277-008-0505-9","article-title":"Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation","volume":"87","author":"Bergua","year":"2008","journal-title":"Ann Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report","volume":"127","author":"Pitini","year":"2004","journal-title":"Br J Haematol."},{"key":"B22","first-page":"17","article-title":"Cell clonality in hypereosinophilic syndrome: what pathogenetic role?","volume":"25","author":"Galimberti","year":"2007","journal-title":"Clin Exp Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3324\/haematol.2008.005447","article-title":"T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome","volume":"94","author":"Helbig","year":"2009","journal-title":"Haematologica."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B25","first-page":"753","article-title":"6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome","volume":"90","author":"Ravoet","year":"2005","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.amjmed.2016.02.013","article-title":"Methylprednisolone-induced lymphocytosis in patients with immune-mediated inflammatory disorders","volume":"129","author":"Bromberg","year":"2016","journal-title":"Am J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/0091-6749(94)90348-4","article-title":"Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa","volume":"94","author":"Butterfield","year":"1994","journal-title":"J Allergy Clin Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1172\/JCI118417","article-title":"Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells","volume":"97","author":"Schandene","year":"1996","journal-title":"J Clin Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fmed.2017.00240","article-title":"Clinical and biological markers in hypereosinophilic syndromes","volume":"4","author":"Khoury","year":"2017","journal-title":"Front Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1182\/blood.V96.13.4285","article-title":"Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia","volume":"96","author":"Schandene","year":"2000","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1111\/bjh.16332","article-title":"Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome","volume":"188","author":"Choi","year":"2020","journal-title":"Br J Haematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jdcr.2019.05.026","article-title":"Lymphocyte-variant hypereosinophilic syndrome presenting as chronic dermatitis and responding to mycophenolic acid","volume":"5","author":"Dou","year":"2019","journal-title":"JAAD Case Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3389\/fimmu.2018.01198","article-title":"Efficacy and safety of mepolizumab (anti-interleukin-5) treatment in gleich's syndrome","volume":"9","author":"Matucci","year":"2018","journal-title":"Front Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jaip.2019.04.039","article-title":"Romidepsin is an effective and well-tolerated therapy in CD3\u2212CD4+ lymphocyte-variant hypereosinophilic syndrome: a case report","volume":"7","author":"Baulier","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-Term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/ddg.13926_g","article-title":"Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab","volume":"17","author":"Buttgereit","year":"2019","journal-title":"J Dtsch Dermatol Ges."},{"key":"B40","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J Invest Dermatol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01765\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T07:40:02Z","timestamp":1597131602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01765\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2020.01765"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01765","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"article-number":"1765"}}